Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.
Francisco Javier NarváezElena CañadillasIvan CastellviJuan José Alegre SanchoVanesa Vincens-ZygmuntGuadalupe BermudoPaola Vidal-MontalMaria Molina-MolinaJoan Miquel NollaPublished in: Arthritis research & therapy (2024)
Based on our results, RTX appears to be effective as rescue therapy in most patients with recurrent or progressive ASS-ILD unresponsive to conventional treatment. The use of RTX was well tolerated in the majority of patients.